This page shows the publications co-authored by Mari Mino-Kenudson and Lucian Chirieac.
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010 Mar 01; 16(5):1561-71.
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23.
The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. Pathology. 2021 Jun; 53(4):446-453.
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021 02; 34(2):380-395.
Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol. 2020 02; 33(2):281-296.
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 2019 03; 14(3):377-407.
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018 09; 13(9):1302-1311.
Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol. 2018 02; 13(2):205-217.
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53.
Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):11021.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.